HISTORY OFFERS many excellent lessons for our science and technology development; but for that we need to know the past. Not the fabled past of mythical times based on folklore and imagined technical prowess, but the more recent history of modern India, when a poor, struggling nation set itself some ambitious targets. One of the more fascinating aspects of this history is the setting up of a penicillin manufacturing factory in the 1950s. Almost anyone with interest in pharmaceuticals knows about Hindustan Antibiotics, the first factory in the Third World to start production of critical drugs in 1954. Few, however, are aware of the ideological battles that were fought as Jawaharlal Nehru pondered the path of development that his newly independent country should pursue, when access to technology was elusive, resources were scarce and drug multinationals were determined to control markets through their know-how and patents. Why is this of any relevance now? Simply because we have not learned the lessons of the past.
What triggered this column's plunge into history was a small news item about the enormous sums the government had spent on procuring vaccines to fight the SARS-COV-2 pandemic. It reflected the concerns that India's first prime minister grappled with while dealing with the question of setting up manufacturing projects in the country and in particular, the penicillin project. The news report of August 4 said the Government of India had spent, till July 31, 2023, a total of ₹36,397 crore on COVID-19 vaccines. The big payout was to the Serum Institute of India, a contract manufacturer for Covishield, the vaccine developed by British multinational AstraZeneca. It received 25,583 crore for 1.3 billion doses, while Bharat Biotech, makers of the indigenously developed Covaxin earned ₹7,301 crore for 35 million doses. These figures reveal how far we are from the goal of self-reliance in pharma that Nehru had hoped for.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.